Source:http://linkedlifedata.com/resource/pubmed/id/15184207
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2004-10-26
|
| pubmed:abstractText |
Mometasone furoate (MF) and fluticasone propionate (FP) are high potency inhaled corticosteroids. The systemic bioavailability of MF is claimed to be negligible, leading to a minimal potential for systemic adverse effects. We assessed the overnight urinary cortisol/creatinine as the primary outcome of adrenal suppression in 21 patients with persistent asthma (mean FEV1 = 91%). Patients were randomized in a crossover fashion to receive 2 weekly consecutive doubling incremental doses of either FP Accuhaler (500, 1,000, and 2,000 microg/day) or MF Twisthaler (400, 800, and 1,600 microg/day). For the 21 per protocol completed patients, there was significant suppression of overnight urinary cortisol/creatinine with high and medium doses of both drugs-as geometric mean fold suppression (95% confidence interval) from baseline: FP 2,000 microg, 1.85 (1.21-2.82, p = 0.002); FP 1,000 microg, 1.45 (1.07-1.96, p = 0.02); MF 1,600 microg, 1.92 (1.26-2.93, p = 0.001); and MF 800 microg, 1.39 (1.04-1.88, p = 0.02). For secondary outcomes of 8:00 A.M. plasma cortisol, serum osteocalcin, and early morning urinary cortisol/creatinine, there was significant suppression with MF and FP at the highest dose. Our data refute the assertion that MF has negligible systemic bioavailability and a lower potential for systemic adverse effects compared with FP.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androstadienes,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Hydrocortisone,
http://linkedlifedata.com/resource/pubmed/chemical/Pregnadienediols,
http://linkedlifedata.com/resource/pubmed/chemical/fluticasone,
http://linkedlifedata.com/resource/pubmed/chemical/mometasone furoate
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1073-449X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
170
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
960-6
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15184207-Administration, Inhalation,
pubmed-meshheading:15184207-Adolescent,
pubmed-meshheading:15184207-Adrenal Glands,
pubmed-meshheading:15184207-Adult,
pubmed-meshheading:15184207-Aged,
pubmed-meshheading:15184207-Androstadienes,
pubmed-meshheading:15184207-Asthma,
pubmed-meshheading:15184207-Biological Availability,
pubmed-meshheading:15184207-Confidence Intervals,
pubmed-meshheading:15184207-Creatinine,
pubmed-meshheading:15184207-Cross-Over Studies,
pubmed-meshheading:15184207-Dose-Response Relationship, Drug,
pubmed-meshheading:15184207-Drug Administration Schedule,
pubmed-meshheading:15184207-Female,
pubmed-meshheading:15184207-Follow-Up Studies,
pubmed-meshheading:15184207-Humans,
pubmed-meshheading:15184207-Hydrocortisone,
pubmed-meshheading:15184207-Male,
pubmed-meshheading:15184207-Middle Aged,
pubmed-meshheading:15184207-Multivariate Analysis,
pubmed-meshheading:15184207-Pregnadienediols,
pubmed-meshheading:15184207-Probability,
pubmed-meshheading:15184207-Respiratory Function Tests,
pubmed-meshheading:15184207-Severity of Illness Index,
pubmed-meshheading:15184207-Treatment Outcome,
pubmed-meshheading:15184207-Urinalysis
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.
|
| pubmed:affiliation |
Asthma and Allergy Research Group, Department of Medicine and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|